Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.06+0.02 (+1.92%)
Close on Nov 17, 2026Market cap $106.36MP/E –Yield –
Cellectis price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Cellectis's price to book ratio was 3.4× on Nov 11, 2026, against 5.2× a year earlier. Over the last 5 years it ranged from 0.5× to 8.2×, with a median of 1.3×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.4× | −1.6 |
| 2025 | Dec 31, 2025 | 5.0× | +3.8 |
| 2024 | Dec 31, 2024 | 1.2× | −0.6 |
| 2023 | Dec 29, 2023 | 1.8× | +1.3 |
| 2022 | Dec 30, 2022 | 0.6× | −0.8 |
| 2021 | Dec 31, 2021 | 1.3× | −2.4 |
| 2020 | Dec 31, 2020 | 3.7× | +2.0 |
| 2019 | Dec 31, 2019 | 1.8× | −0.5 |
| 2018 | Dec 31, 2018 | 2.3× | −1.5 |
| 2017 | Dec 29, 2017 | 3.8× | +1.7 |
| 2016 | Dec 30, 2016 | 2.1× | −10.3 |
| 2015 | Dec 31, 2015 | 12.4× | – |
See a number that looks wrong?